Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies

[1]  J. Oldenburg,et al.  Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management , 2020, Hämostaseologie.

[2]  J. Astermark,et al.  Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples , 2020, Research and practice in thrombosis and haemostasis.

[3]  E. Santagostino,et al.  WFH Guidelines for the Management of Hemophilia, 3rd edition , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  B. Konkle,et al.  Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A , 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  S. Kitchen,et al.  Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  S. Kitchen,et al.  Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors’ Organisation guideline , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[7]  M. Ezban,et al.  A field study evaluating the activity of N8‐GP in spiked plasma samples at clinical haemostasis laboratories , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  D. Perry,et al.  Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice , 2019, Journal of thrombosis and haemostasis : JTH.

[9]  E. Persson,et al.  FIXing postinfusion monitoring: Assay experiences with N9‐GP (nonacog beta pegol; Refixia®; Rebinyn®) , 2019, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  L. Alberio,et al.  Impact of a product‐specific reference standard for the measurement of a PEGylated rFVIII activity: the Swiss Multicentre Field Study , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  I. Pabinger,et al.  Safety and efficacy of BAY 94‐9027, a prolonged‐half‐life factor VIII , 2017, Journal of thrombosis and haemostasis : JTH.

[12]  P. Giangrande,et al.  Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A , 2016, Thrombosis and Haemostasis.

[13]  J. Oldenburg,et al.  A critical appraisal of one‐stage and chromogenic assays of factor VIII activity , 2016, Journal of thrombosis and haemostasis : JTH.

[14]  B. Konkle,et al.  Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. , 2015, Blood.

[15]  J. Dodt,et al.  Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators , 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

[16]  V. Laux,et al.  Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  J. Dumont,et al.  Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. , 2014, Blood.

[18]  S. Kitchen,et al.  Standards and monitoring treatment , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  M. Hamill,et al.  Value assignment of the WHO 2nd International Standard von Willebrand factor, concentrate (09/182) , 2011, Journal of thrombosis and haemostasis : JTH.

[20]  J. Ingerslev,et al.  Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one‐stage clotting assays , 2004, Journal of thrombosis and haemostasis : JTH.

[21]  P. Mannucci,et al.  A multicenter pharmacokinetic study of the B‐domain deleted recombinant factor VIII concentrate using different assays and standards , 2003, Journal of thrombosis and haemostasis : JTH.

[22]  C. Kessler,et al.  Influence of phospholipids on the assessment of factor VIII activity , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[23]  M. Blombäck,et al.  Clinical Application of a Chromogenic Substrate Method for Determination of Factor VIII Activity , 1985, Thrombosis and Haemostasis.

[24]  S. Raut,et al.  Calibration of the Ph. Eur. human coagulation Factor VIII Concentrate BRP batch 6. , 2021, Pharmeuropa bio & scientific notes.